What Barcode does

Barcode Nanotech is a privately held Israeli biotechnology company founded in 2017 and headquartered in Nazareth, Israel. The company develops lipid nanoparticle (LNP) delivery vehicles designed to transport RNA and DNA-based therapeutics and vaccines to specific tissues and cells beyond the liver, addressing a central bottleneck in the RNA therapeutics field where conventional LNPs are predominantly liver-tropic. Its core platform combines an in vivo mass screening capability using molecular barcoding to simultaneously evaluate hundreds of nanoparticle formulations in a single experiment with AI analysis tools that select the optimal delivery vehicle for each target tissue, supported by a proprietary library of novel lipids engineered for selective targeting. The platform has demonstrated capability across liver, lung, tumor, brain, kidney, spleen, and vaccine applications.

The company sells to pharmaceutical and biotechnology developers of RNA and DNA-based drugs and vaccines through a B2B partnership-driven go-to-market. Revenue mechanics are expected to flow from licensing fees, milestone payments, royalties, and collaborative R&D services negotiated under individual co-development agreements; pricing is not publicly disclosed. A named strategic co-development partnership is in place with Galmed Pharmaceuticals for a brain-penetrating LNP formulation of Aramchol targeting CNS diseases, with clinical trials targeted for 2026. Barcode operates with a lean 1–10 person team led by CEO and co-founder Ronen Eavri (former J&J, D-Pharm) and CTO and co-founder Annie Sabbah (former MPT Diagnostics, Rambam/Technion), supported by an R&D team leader, a chemistry lead, a molecular biology specialist, and an AI/bioinformatics specialist, along with scientific and medical advisory boards. The company is privately held, was previously funded by a $4 million OurCrowd round in March 2019, and is currently raising capital to scale partnerships and pipeline development.

Name

Barcode

Legal name

Barcode Nanotech

Website

https://barcode-nano.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Barcode Nanotech is an Israeli biotech developing lipid nanoparticle delivery vehicles for RNA and DNA therapeutics. Its AI-coupled in vivo mass screening platform enables selective tissue targeting beyond the liver for pharmaceutical partners developing vaccines and treatments.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Lipid nanoparticle delivery
• RNA therapeutics platform
• Drug delivery technology
• Nanoparticle formulation services
• In vivo screening platform

Headquarters

HQ city

Nazareth

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Partnership and Licensing Deals: Revenue generation through strategic partnerships with pharmaceutical companies for co-development of RNA therapeutics. The company develops proprietary delivery vehicles and partners with drug developers, likely through licensing fees, milestone payments, and potential royalty arrangements.
2. Research and Development Collaborations: Collaborative R&D arrangements with pharma companies to develop custom nanoparticle delivery solutions for specific therapeutic programs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Barcode Nanotech develops and licenses proprietary lipid nanoparticle (LNP) delivery vehicles and an AI-powered in vivo screening platform that enables pharmaceutical partners to deliver RNA and DNA-based therapeutics and vaccines to precise tissue and cellular targets beyond the liver. The company partners with pharma and vaccine developers on co-development, licensing, and R&D collaboration arrangements.

Product overview

Barcode Nanotech offers a unified platform for RNA/DNA therapeutic delivery, comprising three interconnected components: a proprietary lipid library for RNA/DNA encapsulation and delivery, an in vivo mass screening platform using molecular barcoding technology with AI analysis to identify optimal delivery vehicles, and lipid-based nanoparticle formulations. The platform enables development of selective delivery vehicles targeting tissues including liver, lung, tumor, vaccines, kidney, spleen, and brain.

Differentiator

Problem solved

Functional benefit

Products and services

• Proprietary Lipid Library A proprietary library of novel lipids developed for RNA and DNA encapsulation and LNP-based delivery, designed through an in vivo screening platform to enable selective and efficient targeting of designated cells and tissues. Licensed to pharmaceutical partners for use in RNA and DNA-based therapeutics and vaccines.
• In Vivo Mass Screening Platform A proprietary screening platform that uses molecular barcoding to simultaneously evaluate hundreds of lipid nanoparticle formulations in vivo with rapid feedback loops. Identifies and quantifies nanoparticle biodistribution at single-cell resolution and uses AI analysis to select optimal delivery vehicles for each target tissue or cell.
• Lipid-Based Nanoparticle Delivery Vehicles Proprietary lipid-based nanoparticle formulations for delivery of RNA and DNA-based therapies to targets beyond the liver, optimized for selective indications including hard-to-treat cancers, metabolic diseases, and other therapeutic areas. Made available to pharmaceutical partners through co-development and licensing arrangements.

Quantifiable outcome

• Hundreds of delivery vehicles developed and tested for different therapeutic drugs
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• Galmed PharmaceuticalscoreStrategic or Co-development Partner · 9 April 2026Galmed Pharmaceuticals partnered with Barcode Nanotech to develop a brain-penetrating formulation of Aramchol (SCD1 inhibitor) using lipid nanoparticles for treating CNS diseases such as Parkinson's disease. The formulation is based on Barcode's proprietary nanoparticle platform and plans to advance to clinical trials in 2026.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Others

• Cytiva (formerly Precision NanoSystems): Cytiva acquired Precision NanoSystems, a provider of LNP formulation instruments and lipid libraries used by RNA therapy developers. It is an enabling technology supplier and adjacent competitor whose lipid library offerings overlap with portions of Barcode's proprietary lipid asset.

Emerging players

• Sirnaomics: Sirnaomics is a clinical-stage RNA therapeutics company with its own siRNA and mRNA delivery platforms targeting tumors and fibrotic diseases. It is an emerging peer with partial overlap in delivery-driven RNA approaches for oncology and metabolic indications that Barcode also pursues.
• CureVac: CureVac is an mRNA technology company developing its own lipid delivery formulations for vaccines and therapeutics. It is an emerging player that competes with Barcode for partnerships where RNA delivery know-how is a key differentiator, and overlaps on the RNA vaccine delivery use case.
• Eveon: Eveon develops microfluidic formulation and manufacturing platforms for lipid nanoparticles and complex injectable drugs. It is an emerging peer addressing the same LNP formulation and process development market that Barcode's platform touches through its proprietary lipid library and screening workflow.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the established leader in RNA-targeted therapeutics (siRNA) with proprietary conjugate-based delivery (GalNAc) and growing LNP programs. It is a broad incumbent addressing many of the same therapeutic indications Barcode targets, and represents the type of large pharma partner Barcode's LNP platform is designed to serve.
• BioNTech: BioNTech is a vertically integrated mRNA therapeutics company with internal LNP capabilities and the resources to develop next-generation delivery formulations. It is a broad incumbent that competes with Barcode both as a potential partner and a potential internal-development alternative for pharma partners evaluating LNP technologies.
• Moderna: Moderna operates one of the largest internal LNP and mRNA delivery programs globally, with extensive in-house lipid libraries and biodistribution know-how. It is a broad incumbent whose size and resources set the benchmark Barcode's differentiated screening platform must beat on cost, speed, or tissue selectivity.

Direct peers

• Acuitas Therapeutics: Acuitas is the leading independent LNP delivery technology company, supplying ionizable lipids used in Comirnaty and other approved RNA therapeutics. It is the most directly comparable peer to Barcode, competing head-to-head for pharma LNP licensing deals targeting tissues beyond the liver.
• Genevant Sciences: Genevant develops lipid nanoparticle and other delivery technologies for RNA therapeutics, licensing its platform to multiple pharma partners. It competes directly with Barcode for enterprise partnerships and embodies the same platform-licensing business model.
• Arcturus Therapeutics: Arcturus combines proprietary LNP delivery technology with its own RNA therapeutic pipeline, including rare disease and infectious disease programs. It is a direct peer in the targeted RNA delivery space and operates a hybrid licensing-plus-product model similar to where Barcode could evolve.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/barcode-nanotech/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barcode